NFKB1 and lymphoma: In conclusion, biological validation results were successfully obtained for these pathway models, including on sample data from patients with various diseases, i.e., for the NFκB pathway model allergic contact dermatitis, multiple sclerosis, and lymphomas, for the HH pathway BCC and medulloblastoma, and for the AR pathway PCa.